Compare Sana Biotechnology Inc (SANA) vs T1 Energy Inc. Common Stock (TE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs T1 Energy Inc. Common Stock — how do they compare? Sana Biotechnology Inc trades at $2.33 (market cap $697.51M), while T1 Energy Inc. Common Stock trades at $2.71 (market cap $868.55M). The key difference: T1 Energy Inc. Common Stock is the larger of the two by market cap, and T1 Energy Inc. Common Stock is more actively traded (19,771,934 versus 2,763,583). Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 24 Days and T1 Energy Inc. Common Stock for 0 Days on average.
| SANA | TE | |
|---|---|---|
Market Cap | $697.51M | $868.55M |
Volume | 2,763,583 | 19,771,934 |
Sector | Health | Industrials |
52-Week High | $5.92 | $12.04 |
52-Week Low | $2.33 | $2.72 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $610.76M | $1.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.41, down 8.02% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company shows no revenue with substantial losses (-$244.17M net income in 2025) and negative cash flow, though analyst consensus remains strongly positive with 82% buy ratings. Recent investor conference presentations indicate active business development efforts.
The stock presents high-risk speculative potential with strong Wall Street support but faces fundamental challenges including no revenue generation and significant cash burn. Investment opportunity hinges on successful clinical developments, while risks include continued operational losses and potential dilution from financing activities.
T1 Energy (TE) trades at $3.16, down 1.56% today, reflecting ongoing investor caution despite a mixed earnings history. The company shows significant revenue growth from $755M in 2025 to $997M in 2026 but remains deeply unprofitable with a -38.49% net margin. Recent news highlights strategic moves toward vertical integration in solar manufacturing and energy storage, including the G2_Austin facility development and new supply agreements, which are central to its growth narrative.
The investment case hinges on execution of vertical integration and policy tailwinds, offering substantial upside to the $8 consensus target, but high execution risk, persistent losses, and regulatory scrutiny present clear dangers. Analyst sentiment is mixed with a Moderate Buy rating, yet the stock's viability depends heavily on future profitability improvements from 2027 onward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About T1 Energy Inc. Common Stock
T1 Energy Inc. manufactures photovoltaic solar modules and cells in US, operating a solar manufacturing facility in Texas acquired from Trina Solar. The company was formerly known as FREYR Battery before rebranding as T1 Energy in 2025 and changing its NYSE ticker from FREY to TE.
Read more on TE →
